Biogen (BIIB) EBITDA Margin: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$212.50+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB EBITDA Margin Metrics

EBITDA MARGIN

28.67%

EBITDA MARGIN AVG TTM

20.07%

EBITDA MARGIN AVG 3Y

27.49%

EBITDA MARGIN AVG 5Y

28.50%

EBITDA MARGIN AVG 10Y

36.85%

EBITDA MARGIN AVG 15Y

41.21%

EBITDA MARGIN AVG 20Y

40.48%

CURRENT VS TTM AVG

+42.88%

CURRENT VS 3Y AVG

+4.28%

CURRENT VS 5Y AVG

+0.61%

CURRENT VS 10Y AVG

-22.20%

CURRENT VS 15Y AVG

-30.43%

CURRENT VS 20Y AVG

-29.17%

NAME	MARKET CAP	EBITDA MARGIN	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.40B	28.67%	20.07%	27.49%	28.50%
DexCom, Inc. (DXCM)vs ›	$31.90B	24.96%	22.62%	21.42%	19.95%
Centene Corp. (CNC)vs ›	$31.90B	-3.26%	-0.27%	1.02%	1.75%
Zoetis Inc. (ZTS)vs ›	$30.86B	43.14%	42.58%	42.20%	41.87%
ResMed Inc. (RMD)vs ›	$32.06B	36.98%	37.16%	34.64%	34.36%
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.16B	16.19%	16.24%	16.31%	17.37%
Waters Corporation (WAT)vs ›	$30.13B	34.73%	34.58%	34.05%	33.84%
Medline Inc. (MDLN)vs ›	$29.33B	10.26%	11.41%	10.38%	10.38%
Alcon Inc. (ALC)vs ›	$33.71B	24.53%	25.59%	24.02%	22.67%
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$34.80B	15.00%	4.83%	-18.55%	-52.26%

NAME

MARKET CAP

EBITDA MARGIN

TTM

Biogen Inc. (BIIB)

$31.40B

28.67%

20.07%

27.49%

28.50%

DexCom, Inc. (DXCM)vs ›

$31.90B

24.96%

22.62%

21.42%

19.95%

Centene Corp. (CNC)vs ›

$31.90B

-3.26%

-0.27%

1.02%

1.75%

Zoetis Inc. (ZTS)vs ›

$30.86B

43.14%

42.58%

42.20%

41.87%

ResMed Inc. (RMD)vs ›

$32.06B

36.98%

37.16%

34.64%

34.36%

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.16B

16.19%

16.24%

16.31%

17.37%

Waters Corporation (WAT)vs ›

$30.13B

34.73%

34.58%

34.05%

33.84%

Medline Inc. (MDLN)vs ›

$29.33B

10.26%

11.41%

10.38%

Alcon Inc. (ALC)vs ›

$33.71B

24.53%

25.59%

24.02%

22.67%

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$34.80B

15.00%

4.83%

-18.55%

-52.26%

EBITDA Margin FAQ

What is the EBITDA margin for Biogen Inc. (BIIB)?

The EBITDA margin for BIIB stock is 28.67%.

Is Biogen Inc.'s EBITDA margin high or low?

The EBITDA margin of 28.67% is in line with its 5-year average of 28.50%, around the middle of its 5-year range (2.86%–41.37%).

What is the TTM average EBITDA margin for Biogen Inc. (BIIB)?

The TTM average EBITDA margin for BIIB stock is 20.07%.

What is the 3Y average EBITDA margin for Biogen Inc. (BIIB)?

The 3Y average EBITDA margin for BIIB stock is 27.49%.

What is the 5Y average EBITDA margin for Biogen Inc. (BIIB)?

The 5Y average EBITDA margin for BIIB stock is 28.50%.

What is the 10Y average EBITDA margin for Biogen Inc. (BIIB)?

The 10Y average EBITDA margin for BIIB stock is 36.85%.

What is the 15Y average EBITDA margin for Biogen Inc. (BIIB)?

The 15Y average EBITDA margin for BIIB stock is 41.21%.

What is the 20Y average EBITDA margin for Biogen Inc. (BIIB)?

The 20Y average EBITDA margin for BIIB stock is 40.48%.

DATE	EBITDA MARGIN
2026-06-30	2.86%
2026-03-31	21.55%
2025-12-31	13.10%
2025-09-30	33.24%
2025-06-30	29.57%
2025-03-31	37.67%
2024-12-31	28.23%
2024-09-30	30.82%
2024-06-30	21.32%
2024-03-31	36.58%
2023-12-31	27.34%
2023-09-30	17.62%
2023-06-30	32.86%
2023-03-31	27.88%
2022-12-31	26.65%
2022-09-30	39.49%
2022-06-30	41.37%
2022-03-31	26.36%
2021-12-31	23.47%
2021-09-30	33.57%
2021-06-30	21.19%
2021-03-31	39.96%
2020-12-31	-7.74%
2020-09-30	35.58%
2020-06-30	56.70%
2020-03-31	54.88%
2019-12-31	51.50%
2019-09-30	53.33%
2019-06-30	57.31%
2019-03-31	46.53%
2018-12-31	45.26%
2018-09-30	53.93%
2018-06-30	41.25%
2018-03-31	54.41%
2017-12-31	49.71%
2017-09-30	59.50%
2017-06-30	44.95%
2017-03-31	54.67%
2016-12-31	35.45%
2016-09-30	54.32%
2016-06-30	56.52%
2016-03-31	56.04%
2015-12-31	46.65%
2015-09-30	54.84%
2015-06-30	53.16%
2015-03-31	49.54%
2014-12-31	49.89%
2014-09-30	52.23%
2014-06-30	47.61%
2014-03-31	38.86%
2013-12-31	41.52%
2013-09-30	45.52%
2013-06-30	45.32%
2013-03-31	42.77%
2012-12-31	36.64%
2012-09-30	43.88%
2012-06-30	41.97%
2012-03-31	35.09%
2011-12-31	37.52%
2011-09-30	55.19%
2011-06-30	41.46%
2011-03-31	42.28%
2010-12-31	36.85%
2010-09-30	24.18%
2010-06-30	39.86%
2010-03-31	34.83%
2009-12-31	42.29%
2009-09-30	41.95%
2009-06-30	31.98%
2009-03-31	41.21%
2008-12-31	41.82%
2008-09-30	43.32%
2008-06-30	40.50%
2008-03-31	37.46%
2007-12-31	40.83%
2007-09-30	28.63%
2007-06-30	38.66%
2007-03-31	37.79%
2006-12-31	-272.07%
2006-09-30	40.80%
2006-06-30	-7.02%
2006-03-31	48.47%
2005-12-31	-250.99%
2005-09-30	21.96%
2005-06-30	23.96%
2005-03-31	29.16%
2004-12-31	-587.83%
2004-09-30	36.90%
2004-06-30	18.58%
2004-03-31	3.31%
2003-12-31	351.52%
2003-09-30	54.33%
2003-06-30	37.35%
2003-03-31	56.50%
2002-12-31	31.74%
2002-09-30	27.71%

DATE

EBITDA MARGIN

2026-06-30

2.86%

2026-03-31

21.55%

2025-12-31

13.10%

2025-09-30

33.24%

2025-06-30

29.57%

2025-03-31

37.67%

2024-12-31

28.23%

2024-09-30

30.82%

2024-06-30

21.32%

2024-03-31

36.58%

2023-12-31

27.34%

2023-09-30

17.62%

2023-06-30

32.86%

2023-03-31

27.88%

2022-12-31

26.65%

2022-09-30

39.49%

2022-06-30

41.37%

2022-03-31

26.36%

2021-12-31

23.47%

2021-09-30

33.57%

2021-06-30

21.19%

2021-03-31

39.96%

2020-12-31

-7.74%

2020-09-30

35.58%

2020-06-30

56.70%

2020-03-31

54.88%

2019-12-31

51.50%

2019-09-30

53.33%

2019-06-30

57.31%

2019-03-31

46.53%

2018-12-31

45.26%

2018-09-30

53.93%

2018-06-30

41.25%

2018-03-31

54.41%

2017-12-31

49.71%

2017-09-30

59.50%

2017-06-30

44.95%

2017-03-31

54.67%

2016-12-31

35.45%

2016-09-30

54.32%

2016-06-30

56.52%

2016-03-31

56.04%

2015-12-31

46.65%

2015-09-30

54.84%

2015-06-30

53.16%

2015-03-31

49.54%

2014-12-31

49.89%

2014-09-30

52.23%

2014-06-30

47.61%

2014-03-31

38.86%

2013-12-31

41.52%

2013-09-30

45.52%

2013-06-30

45.32%

2013-03-31

42.77%

2012-12-31

36.64%

2012-09-30

43.88%

2012-06-30

41.97%

2012-03-31

35.09%

2011-12-31

37.52%

2011-09-30

55.19%

2011-06-30

41.46%

2011-03-31

42.28%

2010-12-31

36.85%

2010-09-30

24.18%

2010-06-30

39.86%

2010-03-31

34.83%

2009-12-31

42.29%

2009-09-30

41.95%

2009-06-30

31.98%

2009-03-31

41.21%

2008-12-31

41.82%

2008-09-30

43.32%

2008-06-30

40.50%

2008-03-31

37.46%

2007-12-31

40.83%

2007-09-30

28.63%

2007-06-30

38.66%

2007-03-31

37.79%

2006-12-31

-272.07%

2006-09-30

40.80%

2006-06-30

-7.02%

2006-03-31

48.47%

2005-12-31

-250.99%

2005-09-30

21.96%

2005-06-30

23.96%

2005-03-31

29.16%

2004-12-31

-587.83%

2004-09-30

36.90%

2004-06-30

18.58%

2004-03-31

3.31%

2003-12-31

351.52%

2003-09-30

54.33%

2003-06-30

37.35%

2003-03-31

56.50%

2002-12-31

31.74%

2002-09-30

27.71%

EBITDA Margin: 28.67%

BIIB EBITDA Margin

BIIB Average EBITDA Margin Chart

BIIB Current vs Average EBITDA Margin Chart

BIIB EBITDA Margin Metrics

BIIB Competitors' EBITDA Margin

Margin Comparison

EBITDA Margin Formula & Definition

EBITDA Margin FAQ

BIIB EBITDA Margin History

Related Metrics